ORGAN SYSTEM SUPPORTED

The type of organ system supported within a CRITICAL CARE PERIOD. This may not necessarily be support for a failing organ. Basic respiratory support will frequently occur prior to advanced respiratory support. If they are both required on the same day, only advanced respiratory support must be recorded. Basic cardiovascular support will frequently occur prior to advanced cardiovascular support. If they are both required on the same day, only advanced cardiovascular support must be recorded.

National Codes:

01Basic Respiratory Support. Indicated by one or more of the following:
  • More than 50% oxygen delivered by face mask. (Note: more than 50% has been chosen to identify the more seriously ill PATIENTS  in a hospital). Short-term increases in the fraction of inspired oxygen (FiO2) to facilitate procedures such as transfers or physiotherapy do not qualify.
  • Close observation due to the potential for acute deterioration to the point of needing advanced respiratory support. (e.g. severely compromised airway or deteriorating respiratory muscle function).
  • Physiotherapy or suction to clear secretions at least two hourly, whether via tracheostomy, minitracheostomy, or in the absence of an artificial airway.
  • PATIENTS recently (within 24 hours) extubated after a period (greater than 24 hours) of mechanical ventilation via an endotracheal tube.
  • Mask / hood continuous positive airway pressure (CPAP) or mask / hood Bi-level positive airway pressure ventilation (non-invasive ventilation).
  • PATIENTS who are intubated to protect the airway but needing no ventilatory support.
  • Continuous positive airway pressure (CPAP) via a tracheostomy. Note: The presence of a tracheostomy used for long term airway access only does not qualify for any respiratory support.
02Advanced Respiratory Support. Indicated by:
  • Invasive mechanical ventilatory support applied via a trans-laryngeal tracheal tube or applied via a tracheostomy
  • Bi-level positive airway pressure applied via a trans-laryngeal tracheal tube or applied via a tracheostomy.
  • Continuous positive airway pressure via a trans-laryngeal tracheal tube.
  • Extracorporeal respiratory support.
03Basic Cardiovascular Support. Indicated by one or more of the following:
  • Use of a central venous pressure (CVP) line for monitoring of central venous pressure and/or provision of central venous access to deliver titrated fluids to treat hypovolaemia.
  • Use of an arterial line for monitoring of arterial pressure and/or sampling of arterial blood.
  • Single intravenous vasoactive drug used to support or control arterial pressure, cardiac output or organ perfusion.
  • Single intravenous rhythm controlling drug to support or control cardiac arrhythmias.
04Advanced Cardiovascular Support. Indicated by one or more of the following:
  • Multiple intravenous vasoactive and/or rhythm controlling drugs when used simultaneously to support or control arterial pressure, cardiac output or organ perfusion (eg inotropes, amiodarone, nitrates). To qualify for advanced support status, at least one drug needs to be vasoactive.
  • Continuous observation of cardiac output and derived indices (e.g. pulmonary artery catheter, lithium dilution, pulse contour analyses, oesophageal doppler).
  • Intra aortic balloon pumping and other assist devices.
  • Insertion of a temporary cardiac pacemaker (criteria valid for each day of connection to a functioning external pacemaker unit).
05Renal Support. In the context of critical illness, this is indicated by:
  • Acute renal replacement therapy (e.g. haemodialysis, haemofiltration etc.) or the provision of renal replacement therapy to a chronic renal failure patient who is requiring other acute organ support in a critical care situation.
06Neurological Support. Indicated by one or more of the following:
  • Central nervous system depression sufficient to prejudice the airway and protective reflexes, excepting that caused by sedation prescribed to facilitate mechanical ventilation or poisoning (e.g. deliberate or accidental overdose, alcohol, drugs, etc.)
  • Invasive neurological monitoring e.g. intracranial pressure, jugular bulb sampling, external ventricular drain.
  • Continuous intravenous medication to control seizures and/or continuous cerebral monitoring.
  • Therapeutic hypothermia using cooling protocols or devices.
07Gastrointestinal Support. Indicated by:
  • Feeding with parenteral or enteral nutrition (implies methods of feeding other than normal oral intake).
08Dermatological Support. Indicated by one or more of the following:
  • PATIENTS with major skin rashes, exfoliation or burns (eg greater than 30% body surface area affected).
  • Use of complex dressings (e.g. large skin area greater than 30% body surface area, open abdomen, vacuum dressings or large trauma such as multiple limb or limb and head dressings).
09Liver Support. Indicated by:
  • Acute on chronic Hepatocellular failure requiring management of coagulopathy and/or portal hypertension (including liver purification and detoxification techniques), or
  • Primary Acute Hepatocellular failure PATIENTS who are being considered for transplantation and require management of coagulopathy and / or portal hypertension (including liver purification and detoxification techniques).
 

This attribute is also known by these names:
ContextAlias
pluralORGAN SYSTEMS SUPPORTED